Stromal and vascular invasion in an human in vitro bladder cancer model

Laboratory Investigation

Volumn 76, Issue 6, 1997, Pages 843-857

  Booth, Catherine ^a   Harnden, Patricia ^a   Trejdosiewicz, Ludwik K ^a   Scriven, Sharon ^a   Selby, Peter J ^a   Southgate, Jennifer ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; COLLAGEN TYPE 4; CYTOKERATIN; LAMININ;

ARTICLE; BLADDER CANCER; CANCER INVASION; CARCINOMA CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; STROMA; TRANSITIONAL CELL CARCINOMA; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; CARCINOMA, TRANSITIONAL CELL; CULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; ORGANOIDS; STROMAL CELLS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; URINARY TRACT; URINARY TRACT PHYSIOLOGY;

EID: 0031010941     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ahlering TE, Dubeau L, and Jones PA (1987). A new in vivo model to study invasion and metastasis of human bladder carcinoma. Cancer Res 47:6660-6665.
2. Banks RE, Porter WH, Whelan P, Smith PH, and Selby PJ (1995). Soluble forms of the adhesion molecule E-cadherin in urine. J Clin Pathol 48:179-180.
3. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, and Schalken JA (1993). Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53:3241-3245.
4. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, and Balkwill F (1993). Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365-5369.
5. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC, and Fridman R (1996). High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56:1654-1659.
6. Harnden P, Allam A, Joyce AD, Patel A, Selby P, and Southgate J (1995). Cytokeratin 20 expression by non-invasive transitional cell carcinomas: Potential for distinguishing recurrent from non-recurrent disease. Histopathology 27:169-174.
7. Harnden P, Eardley I, Joyce AD, and Southgate J (1996). Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 78:870-875.
8. Harnden P and Parkinson MC (1996). Transitional cell carcinoma of the bladder: Diagnosis and prognosis. Curr Diagn Pathol 3:109-121.
9. Hasui Y, Marutsuka K, Asada Y, and Osada Y (1996). Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 47:34-37.
10. Hembrough TA, Kralovich KR, Li L, and Gonias SL (1996a). Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J 317:763-769.
11. Hembrough TA, Li L, and Gonias SL (1996b). Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem 271:25684-25691.
12. Hembrough TA, Vasudevan J, Allietta MM, Glass WF, and Gonias SL (1995). A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. J Cell Sci 108:1071-1082.
13. Hendrix MJ, Seftor EA, Chu YW, Seftor RE, Nagle RB, McDaniel KM, Leong SP, Yohem KH, Leibovitz AM, Meyskens FL, Conaway DH, Welch DR, Liotta LA, and Stelter-Stevenson W (1992). Coexpression of vimentin and keratins by human melanoma tumor cells: Correlation with invasive and metastatic potential. J Natl Cancer Inst 84:165-174.
14. Hutton KA, Trejdosiewicz LK, Thomas DF, and Southgate J (1993). Urothelial tissue culture for bladder reconstruction: An experimental study. J Urol 150:721-725.
15. Kanal Y, Oda T, Tsuda H, Ochiai A, and Hirohashi S (1994). Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res 85:1035-1039.
16. Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M, and Kato I (1994). Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 69: 580-585.
17. Kroft SH and Oyasu R (1994). Urinary bladder cancer: Mechanisms of development and progression. Lab Invest 71:158-174.
18. Liebert M, Washington R, Wedemeyer G, Carey TE, and Grossman HB (1994). Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer. Am J Pathol 144:787-795.
19. Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, Parkar M, Hill BT, Riddle PR, and Franks LM (1986). Tissue culture model of transitional cell carcinoma: Characterization of twenty-two human urothelial cell lines. Cancer Res 46:3630-3636.
20. Moll R, Achtstatter T, Becht E, Balcarova-Stander J, Ittensohn M, and Franke WW (1988). Cytokeratins in normal and malignant transitional epithelium: Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines. Am J Pathol 132:123-144.
21. Moll R, Franke WW, Schiller DL, Geiger B, and Krepler R (1982). The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11-24.
22. Muschel RJ, Tykocinski M, and Padarathsingh M (1996). Link between tumor progression, proteases, and cell motility (Pathology B workshop). Am J Pathol 149:1073-1076.
23. Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rubben H, and Raz A (1994). Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 54:3120-3123.
24. Rebel JM, Thijssen CD, Vermey M, Zwarthoff EC, and Van der Kwast TH (1995). Modulation of intra-epithelial expansion of human T24 bladder-carcinoma cells in murine urothelium by growth factors and extracellular-matrix components. Int J Cancer 60:707-711.
25. Redwood SM, Liu BC, Weiss RE, Hodge DE, and Droller MJ (1992). Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer 69:1212-1219.
26. Rieger KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, Libertino JA, and Summerhayes IC (1995). Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer 72:683-690.
27. Ross JS, del Rosario AD, Figge HL, Sheehan C, Fisher HA, and Bui HX (1995). E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol 26:940-944.
28. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, and Reuter VE (1993). Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 85:53-59.
29. Schaafsma HE, Ramaekers FC, van Muijen GN, Lane EB, Leigh IM, Robben H, Huijsmans A, Ooms EC, and Ruiter DJ (1990). Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression. Am J Pathol 136:329-343.
30. Schaafsma HE, Ramaekers FC, van Muijen GN, Robben H, Lane EB, Leigh IM, Ooms EC, Schalken JA, van Moorselaar RJ, and Ruiter DJ (1991). Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract: An immunohistochemical study comparing local tumor and autologous metastases. Am J Pathol 139:1389-1400.
31. Schlussel RN, Droller MJ, and Liu BC (1991). Type IV procollagen mRNA regulation: Evidence for extracellular matrix/ cytoskeleton/nuclear matrix interactions in human urothelium. J Urol 146:428-432.
32. Schwartz GK, Redwood SM, Ohnuma T, Holland JF, Droller MJ, and Liu BC (1990). Inhibition of invasion of invasive human bladder carcinoma cells by protein kinase C inhibitor staurosporine. J Natl Cancer Inst 82:1753-1756.
33. Scriven SD, Thomas DFM, Trejdosiewicz LK, and Southgate J (in press, 1997). Reconstitution of human urothelium from monolayer tissue cultures: Use in composite enterocystoplasty. J Urol.
34. Shibata T, Ochiai A, Kanai Y, Akimoto S, Gotoh M, Yasui N, Machinami R, and Hirohashi S (1996). Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 13:883-889.
35. Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S, and Hirohashi S (1992). Cadherin dysfunction in a human cancer cell line: Possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness. Cancer Res 52:5770-5774.
36. Silen A, Wiklund B, Andersson EL, and Nilsson S (1995). A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients. Scan J Clin Lab Invest 55:153-161.
37. Southgate J, Hutton KA, Thomas DF, and Trejdosiewicz LK (1994). Normal human urothelial cells in vitro: Proliferation and induction of stratification. Lab Invest 71:583-594.
38. Southgate J, Proffitt J, Roberts P, Smith B, and Selby P (1995). Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. Br J Cancer 72:1214-1218.
39. Southgate J and Tredjdosiewicz LK (1997). Immunolabelling of cells and tissues: Approaches and pitfalls. Hum Fertil 1:101-111.
40. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG, and Jones PA (1994). Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784-788.
41. Syrigos KN, Krausz T, Waxman J, Pandha H, Rowlinson-Busza G, Verne J, Epenetos AA, and Pignatelli M (1995). E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: Correlation with histopathological grade, tumour stage and survival. Int J Cancer 64:367-370.
42. Trejdosiewicz LK, Southgate J, Donald JA, Masters JR, Hepburn PJ, and Hodges GM (1985). Monoclonal antibodies to human urothelial cell lines and hybrids: Production and characterization. J Urol 133:533-538.
43. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, and Hirohashi S (1995). Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92:7416-7419.